Interstitial lung disorders following postoperative radiotherapy with concurrent or sequential hormonal therapy for breast cancer: a nationwide database study in Japan.
Adjuvant therapy
Antineoplastic hormonal drugs
Breast cancer
Radiation pneumonitis
Radiotherapy
Journal
Breast cancer (Tokyo, Japan)
ISSN: 1880-4233
Titre abrégé: Breast Cancer
Pays: Japan
ID NLM: 100888201
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
25
11
2021
accepted:
13
02
2022
pubmed:
27
2
2022
medline:
28
6
2022
entrez:
26
2
2022
Statut:
ppublish
Résumé
Hormonal therapy and radiotherapy are conducted concurrently or sequentially after breast cancer surgery. It remains unclear whether concurrent or sequential treatment is safer in terms of lung complications. Using a Japanese nationwide database, this study aimed to compare the occurrence of severe lung complications between concurrent and sequential treatments. We identified patients who underwent partial mastectomy for stage 0-III breast cancer from July 2010 to March 2020 and received adjuvant hormonal therapy and radiotherapy concurrently (n = 1851) or sequentially (n = 18,429). Two propensity score analyses (1:4 matching and overlap weighting) were conducted to compare hospitalization for radiation pneumonitis and pneumonia within 1 year after surgery, and intensive care unit admission and mortality during the hospitalization. We conducted additional analyses stratified by hormonal drugs (aromatase inhibitors and tamoxifen). The propensity score-matched analysis showed no significant differences in occurrence of hospitalization for radiation pneumonitis (0.27 vs. 0.58%, p = 0.10) and pneumonia (0.16 vs. 0.58%, p = 0.05) between the concurrent and sequential treatments. The overlap propensity score-weighted analysis also showed no significant differences (0.25 vs. 0.56%, p = 0.08 and 0.15 vs. 0.44%, p = 0.06, respectively). Intensive care unit admission and in-hospital mortality did not differ significantly between the two treatments. The stratified analysis showed similar results. Our propensity score analyses revealed no significant differences in severe lung complications between concurrent and sequential hormonal therapy with radiotherapy following breast cancer surgery, regardless of the type of hormonal drugs. Clinicians can provide concurrent or sequential treatment with equivalent attention to early lung complications.
Sections du résumé
BACKGROUND
BACKGROUND
Hormonal therapy and radiotherapy are conducted concurrently or sequentially after breast cancer surgery. It remains unclear whether concurrent or sequential treatment is safer in terms of lung complications. Using a Japanese nationwide database, this study aimed to compare the occurrence of severe lung complications between concurrent and sequential treatments.
METHODS
METHODS
We identified patients who underwent partial mastectomy for stage 0-III breast cancer from July 2010 to March 2020 and received adjuvant hormonal therapy and radiotherapy concurrently (n = 1851) or sequentially (n = 18,429). Two propensity score analyses (1:4 matching and overlap weighting) were conducted to compare hospitalization for radiation pneumonitis and pneumonia within 1 year after surgery, and intensive care unit admission and mortality during the hospitalization. We conducted additional analyses stratified by hormonal drugs (aromatase inhibitors and tamoxifen).
RESULTS
RESULTS
The propensity score-matched analysis showed no significant differences in occurrence of hospitalization for radiation pneumonitis (0.27 vs. 0.58%, p = 0.10) and pneumonia (0.16 vs. 0.58%, p = 0.05) between the concurrent and sequential treatments. The overlap propensity score-weighted analysis also showed no significant differences (0.25 vs. 0.56%, p = 0.08 and 0.15 vs. 0.44%, p = 0.06, respectively). Intensive care unit admission and in-hospital mortality did not differ significantly between the two treatments. The stratified analysis showed similar results.
CONCLUSION
CONCLUSIONS
Our propensity score analyses revealed no significant differences in severe lung complications between concurrent and sequential hormonal therapy with radiotherapy following breast cancer surgery, regardless of the type of hormonal drugs. Clinicians can provide concurrent or sequential treatment with equivalent attention to early lung complications.
Identifiants
pubmed: 35217987
doi: 10.1007/s12282-022-01346-0
pii: 10.1007/s12282-022-01346-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
688-697Subventions
Organisme : Ministry of Health, Labour and Welfare
ID : 20AA2005
Organisme : Ministry of Health, Labour and Welfare
ID : 21AA2007
Organisme : Ministry of Education, Culture, Sports, Science and Technology
ID : 20H03907
Informations de copyright
© 2022. The Author(s), under exclusive licence to The Japanese Breast Cancer Society.
Références
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378(9793):771–84. https://doi.org/10.1016/S0140-6736(11)60993-8 .
doi: 10.1016/S0140-6736(11)60993-8
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, et al. Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet. 2011;378(9804):1707–16. https://doi.org/10.1016/S0140-6736(11)61629-2 .
doi: 10.1016/S0140-6736(11)61629-2
Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 2011;12:1101–8. https://doi.org/10.1016/S1470-2045(11)70270-4 .
doi: 10.1016/S1470-2045(11)70270-4
pubmed: 22018631
pmcid: 3235950
Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11:1135–41. https://doi.org/10.1016/S1470-2045(10)70257-6 .
doi: 10.1016/S1470-2045(10)70257-6
pubmed: 21087898
Whelan T, Levine M. Radiation therapy and tamoxifen: concurrent or sequential? That is the question. J Clin Oncol. 2005;23:1–4. https://doi.org/10.1200/JCO.2005.08.955 .
doi: 10.1200/JCO.2005.08.955
pubmed: 15545667
Azria D, Pelegrin A, Dubois J-B, Mirimanoff R-O, Ozsahin M. Radiation therapy and tamoxifen: concurrent or sequential? It’s no longer the question! J Clin Oncol. 2005;23:4239–41. https://doi.org/10.1200/JCO.2005.01.2286 .
doi: 10.1200/JCO.2005.01.2286
pubmed: 15961779
Ishitobi M, Komoike Y, Motomura K, Koyama H, Nishiyama K, Inaji H. Retrospective analysis of concurrent vs. sequential administration of radiotherapy and hormone therapy using aromatase inhibitor for hormone receptor-positive postmenopausal breast cancer. Anticancer Res. 2009;29:4791–4.
pubmed: 20032437
Harris EER, Christensen VJ, Hwang WT, Fox K, Solin LJ. Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. J Clin Oncol. 2005;23:11–6. https://doi.org/10.1200/JCO.2005.09.056 .
doi: 10.1200/JCO.2005.09.056
pubmed: 15545665
Cecchini MJ, Yu E, Potvin K, D’souza D, Lock M. Concurrent or sequential hormonal and radiation therapy in breast cancer: a literature review. Cureus. 2015;7:1–13. https://doi.org/10.7759/cureus.364 .
doi: 10.7759/cureus.364
Katayama N, Sato S, Katsui K, Takemoto M, Tsuda T, Yoshida A, et al. Analysis of factors associated with radiation-induced bronchiolitis obliterans organizing pneumonia syndrome after breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2009;73:1049–54. https://doi.org/10.1016/j.ijrobp.2008.05.050 .
doi: 10.1016/j.ijrobp.2008.05.050
pubmed: 18755559
Bentzen SM, Skoczylas JZ, Overgaard M, Overgaard J. Radiotherapy-related lung fibrosis enhanced by tamoxifen. J Natl Cancer Inst. 1996;88:918–22.
doi: 10.1093/jnci/88.13.918
Huang EY, Wang CJ, Chen HC, Sun LM, Fang FM, Yeh SA, et al. Multivariate analysis of pulmonary fibrosis after electron beam irradiation for postmastectomy chest wall and regional lymphatics: evidence for non-dosimetric factors. Radiother Oncol. 2000;57:91–6. https://doi.org/10.1016/S0167-8140(00)00211-5 .
doi: 10.1016/S0167-8140(00)00211-5
pubmed: 11033193
Koc M, Polat P, Suma S. Effects of tamoxifen on pulmonary fibrosis after cobalt-60 radiotherapy in breast cancer patients. Radiother Oncol. 2002;64:171–5. https://doi.org/10.1016/S0167-8140(02)00136-6 .
doi: 10.1016/S0167-8140(02)00136-6
pubmed: 12242127
Dörr W, Bertmann S, Herrmann T. Radiation induced lung reactions in breast cancer therapy: modulating factors and consequential effects. Strahlenther Onkol. 2005;181:567–73. https://doi.org/10.1007/s00066-005-1457-9 .
doi: 10.1007/s00066-005-1457-9
pubmed: 16170483
Li YF, Chang L, Li WH, Xiao MY, Wang Y, He WJ, et al. Radiotherapy concurrent versus sequential with endocrine therapy in breast cancer: a meta-analysis. Breast. 2016;27:93–8. https://doi.org/10.1016/j.breast.2015.09.005 .
doi: 10.1016/j.breast.2015.09.005
pubmed: 27054754
Yasunaga H. Real world data in Japan: chapter II the diagnosis procedure combination database. Ann Clin Epidemiol. 2019;1:76–9.
doi: 10.37737/ace.1.3_76
Yamana H, Moriwaki M, Horiguchi H, Kodan M, Fushimi K, Yasunaga H. Validity of diagnoses, procedures, and laboratory data in Japanese administrative data. J Epidemiol. 2017;27:476–82. https://doi.org/10.1016/j.je.2016.09.009 .
doi: 10.1016/j.je.2016.09.009
pubmed: 28142051
pmcid: 5602797
Inokuchi M, Kutomi G, Kijima Y, Sakai T, Sawaki M, Shien T, et al. The Japanese Breast Cancer Society clinical practice guidelines for surgical treatment of breast cancer, 2018 edition. Breast Cancer. 2020;27:4–8. https://doi.org/10.1007/s12282-019-01030-w .
doi: 10.1007/s12282-019-01030-w
pubmed: 31832890
Nozaki M, Kagami Y, Shibata T, Nakamura K, Ito Y, Nishimura Y, et al. A primary analysis of a multicenter, prospective, single-arm, confirmatory trial of hypofractionated whole breast irradiation after breast-conserving surgery in Japan: JCOG0906. Jpn J Clin Oncol. 2019;49:57–62. https://doi.org/10.1093/jjco/hyy160 .
doi: 10.1093/jjco/hyy160
pubmed: 30428042
Whelan TJ, Pignol JP, Levine MN, Julian JA, MacKenzie R, Parpia S, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2020;362:513–20. https://doi.org/10.1016/S1043-321X(10)79594-1 .
doi: 10.1016/S1043-321X(10)79594-1
Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–83.
doi: 10.1016/0021-9681(87)90171-8
Yasunaga H. Introduction to applied statistics—chapter 1 propensity score analysis. Ann Clin Epidemiol. 2020;2:33–7. https://doi.org/10.37737/ace.2.2_33 .
doi: 10.37737/ace.2.2_33
Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399–424. https://doi.org/10.1080/00273171.2011.568786 .
doi: 10.1080/00273171.2011.568786
pubmed: 21818162
pmcid: 3144483
Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:1–10. https://doi.org/10.1136/bmj.l5657 .
doi: 10.1136/bmj.l5657
Thomas LE, Li F, Pencina MJ. Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial. JAMA. 2020;323:2417–8. https://doi.org/10.1001/jama.2020.7819 .
doi: 10.1001/jama.2020.7819
pubmed: 32369102
Mehta N, Kalra A, Nowacki AS, Anjewierden S, Han Z, Bhat P, et al. Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5:1020–6. https://doi.org/10.1001/jamacardio.2020.1855 .
doi: 10.1001/jamacardio.2020.1855
pubmed: 32936273
Xian Y, Xu H, O’Brien EC, Shah S, Thomas L, Pencina MJ, et al. Clinical effectiveness of direct oral anticoagulants vs warfarin in older patients with atrial fibrillation and ischemic stroke: findings from the patient-centered research into outcomes stroke patients prefer and effectiveness research (PROSPER) study. JAMA Neurol. 2019;76:1192–202. https://doi.org/10.1001/jamaneurol.2019.2099 .
doi: 10.1001/jamaneurol.2019.2099
pubmed: 31329212
pmcid: 6647003
Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score weighting. J Am Stat Assoc. 2018;113(521):390–400. https://doi.org/10.1080/01621459.2016.1260466 .
doi: 10.1080/01621459.2016.1260466
Yamauchi C, Yoshimura M, Sekiguchi K, Hamamoto Y, Nakajima N, Sanuki N, et al. The Japanese breast cancer society clinical practice guideline for radiation treatment of breast cancer, 2018 edition. Breast Cancer. 2020;27:9–16. https://doi.org/10.1007/s12282-019-01019-5 .
doi: 10.1007/s12282-019-01019-5
pubmed: 31659711
Azria D, Gourgou S, Sozzi WJ, Zouhair A, Mirimanoff RO, Kramar A, et al. Concomitant use of tamoxifen with radiotherapy enhances subcutaneous breast fibrosis in hypersensitive patients. Br J Cancer. 2004;91:1251–60. https://doi.org/10.1038/sj.bjc.6602146 .
doi: 10.1038/sj.bjc.6602146
pubmed: 15328527
pmcid: 2409893
Azria D, Belkacemi Y, Romieu G, Gourgou S, Gutowski M, Zaman K, et al. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. Lancet Oncol. 2010;11:258–65. https://doi.org/10.1016/S1470-2045(10)70013-9 .
doi: 10.1016/S1470-2045(10)70013-9
pubmed: 20138810
Wazer DE, DiPetrillo T, Schmidt-Ullrich R, Weld L, Smith TJ, Marchant DJ, et al. Factors influencing cosmetic outcome and complication risk after conservative surgery and radiotherapy for early-stage breast carcinoma. J Clin Oncol. 1992;10:356–63. https://doi.org/10.1200/JCO.1992.10.3.356 .
doi: 10.1200/JCO.1992.10.3.356
pubmed: 1445509
Ahn PH, Vu HT, Lannin D, Obedian E, DiGiovanna MP, Burtness B, et al. Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates. J Clin Oncol. 2005;23:17–23. https://doi.org/10.1200/JCO.2005.09.048 .
doi: 10.1200/JCO.2005.09.048
pubmed: 15545666
Hack TF, Degner LF, Watson P, Sinha L. Do patients benefit from participating in medical decision making? Longitudinal follow-up of women with breast cancer. Psychooncology. 2006;15:9–19. https://doi.org/10.1002/pon.907 .
doi: 10.1002/pon.907
pubmed: 15669023
Tariman JD, Berry DL, Cochrane B, Schepp AD. Preferred and actual participation roles during health care decision making in persons with cancer: a systematic review. Ann Oncol. 2009;21:1145–51. https://doi.org/10.1093/annonc/mdp534 .
doi: 10.1093/annonc/mdp534
pubmed: 19940010
pmcid: 4200024
Davis LE, Fulton C, Bubis LD, Sussman J, Moody L, Barbera L, et al. Patient-reported symptoms following mastectomy alone or lumpectomy plus radiation for early stage breast cancer: a cohort study. Breast Cancer Res Treat. 2019;175:721–31. https://doi.org/10.1007/s10549-019-05196-x .
doi: 10.1007/s10549-019-05196-x
pubmed: 30879223
Davis LE, Bubis LD, Mahar AL, Li Q, Sussman J, Moody L, et al. Patient-reported symptoms after breast cancer diagnosis and treatment: a retrospective cohort study. Eur J Cancer. 2018;101:1–11. https://doi.org/10.1016/j.ejca.2018.06.006 .
doi: 10.1016/j.ejca.2018.06.006
pubmed: 30014970
Valakh V, Trombetta MG, Werts ED, et al. Influence of concurrent anastrozole on acute and late side effects of whole breast radiotherapy. Am J Clin Oncol. 2011;34:245–8. https://doi.org/10.1097/COC.0b013e3181df4b62 .
doi: 10.1097/COC.0b013e3181df4b62
pubmed: 20622644